BOCA RATON, Fla.--(BUSINESS WIRE)--Mar 4, 2025--
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the publication of a study titled "Keloid Excision With Primary Closure Combined With Superficial Radiation Therapy (SRT-100)" in the Annals of Plastic Surgery.
The single-site, retrospective study evaluated the clinical outcomes of combining surgical excision of keloids with primary wound closure followed by adjuvant Superficial Radiation Therapy (SRT) using Sensus Healthcare's SRT-100 ® system. The findings from follow-up visits involving 12 patients with 16 keloids indicate that no keloid recurrence was observed with most patients followed for more than six months, highlighting the efficacy of this treatment approach. This is Sensus Healthcare’s first study in Asia and was conducted at Tri Service Military Hospital in Taiwan, which has been using the SRT-100 ® since 2023.
"We are delighted to see the SRT-100 ® system featured in this prestigious peer-reviewed publication, further validating its role in keloid management," said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "Keloids can be both physically and emotionally distressing for patients, and traditional treatment approaches often lead to high recurrence rates with even-larger keloids. By integrating SRT following surgical excision, we provide a non-invasive, targeted solution that significantly reduces recurrence and improves patient outcomes. This study reinforces our commitment to advancing clinically proven therapies that enhance quality of life for those suffering from dermatological issues including keloids, which are relatively more prevalent in southeast Asian populations."
Keloids are benign skin tumors that develop due to an abnormal overgrowth of scar tissue, often extending beyond the original wound site. They can cause significant discomfort, itching and even pain, in addition to the cosmetic concerns that may lead to emotional distress. Traditional treatment options, including corticosteroid injections, cryotherapy and laser therapy, often yield inconsistent results and are associated with high recurrence rates.
This study suggests the integration of SRT as an adjunct to surgical excision provides an improved treatment regimen by targeting the root cause of keloid regrowth—excess fibroblast activity—without invasive procedures or prolonged recovery periods. The study's findings further support SRT's ability to significantly reduce recurrence, offering patients a more reliable and effective long-term solution.
The study is accessible online in the March 2025 issue of the Annals of Plastic Surgery.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “approximately,” "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release, as a result of the following factors, among others: the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; the performance of the Company’s information technology systems and its ability to maintain data security; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250304134583/en/
CONTACT: Alliance Advisors IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614
KEYWORD: UNITED STATES TAIWAN NORTH AMERICA ASIA PACIFIC FLORIDA
